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Abstract 1 
Vitamin D is typically supplied in capsule form, both in trials and clinical practice. Yet little is 2 
known regarding the efficacy of vitamin D administered via oral spray; a method that primarily 3 
bypasses the gastrointestinal absorption route. This study aimed to compare the efficacy of vitamin 4 
D3 liquid capsules and oral spray solution, at increasing wintertime total 25-hydroxyvitamin D 5 
[25(OH)D] concentrations. In this randomised, open-label crossover trial, healthy adults (n=22) 6 
received 3000IU (75µg) vitamin D3 daily for 4 weeks in either capsule or oral spray form. 7 
Following a 10-week washout phase, participants received the opposite treatment for a final 4 8 
weeks. Anthropometrics and fasted blood samples were obtained pre and post-supplementation, 9 
with samples analysed for total 25(OH)D, creatinine, intact parathyroid hormone and adjusted 10 
calcium concentrations. At baseline, vitamin D sufficiency [total 25(OH)D >50nmol/L], 11 
insufficiency (31-49nmol/L) and clinical deficiency (<30nmol/L) was evident in 59%, 23% and 12 
18% of participants respectively. Overall, baseline mean ± SD total 25(OH)D concentration 13 
averaged 59.76±29.88nmol/L, representing clinical sufficiency. Analysis of covariance revealed no 14 
significant difference in the mean ± SD change from baseline in total 25(OH)D concentration 15 
between oral spray and capsule supplementation methods (26.15±17.85 versus 30.38±17.91nmol/L 16 
respectively (F=1.044, adjusted r
2
=0.493, P=0.313)). Oral spray vitamin D3 is an equally effective 17 
alternative to capsule supplementation in healthy adults. 18 
 19 
 20 
 21 
 22 
Page 2 of 23
Cambridge University Press
British Journal of Nutrition
For Review Only
3 
 
Introduction 23 
Epidemiological studies have revealed that vitamin D insufficiency and deficiency, defined as a 24 
total 25-hydroxyvitamin D [25(OH)D] concentration below 50 and 30nmol/L respectively, are 25 
endemic worldwide 
(1, 2)
. Such findings have led to significant investment in vitamin D research 26 
with many exploring the impact of vitamin D supplementation on skeletal health as well as 27 
potential extra-skeletal outcomes 
(3-6)
. Scientists investigating the pleotropic role of vitamin D in 28 
randomised controlled trials often use capsules or tablets as a peroral method of nutrient delivery 
(4, 
29 
7)
. However, despite being commercially available, little is known regarding the efficacy of oral 30 
spray vitamin D which is primarily absorbed at the buccal, sublingual and palatal membranes in the 31 
oral cavity rather than the gastrointestinal tract 
(8)
. Emerging evidence also suggests that oral spray 32 
vitamin D may provide an accelerated route of absorption compared to capsules and may be 33 
advantageous in those with gastrointestinal malabsorption 
(9)
. Owing to the lipophilic nature of 34 
vitamin D, oral sprays containing this micronutrient typically contain a triglyceride carrier 35 
substance as well as solubilising excipients, such as α-tocopherol and oleic acid, which promote 36 
passive absorption of the micro-emulsified solution into systemic circulation 
(10)
. This is achieved 37 
through dispersion across capillary beds in the oral submucosa 
(11)
. Following entry into systemic 38 
circulation, vitamin D [including both ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) 39 
compounds] is bound to vitamin D binding proteins and transported to the liver where it undergoes 40 
hydroxylation, catalysed by 25-hydroxylase. This process forms the biomarker of vitamin D status, 41 
25(OH)D, that is subsequently hydroxylated into the biologically active vitamin D metabolite 1,25-42 
dihydroxyvitamin D [1,25(OH)2D] in the kidneys and by cells elsewhere that also express 1α-43 
hydroxylase 
(12)
. Such cells are present throughout the body including sites such as the skeleton, 44 
prostate and immune system 
(13)
. It is 1,25(OH)2D that governs vitamin D-related mechanisms of 45 
action through binding to the vitamin D receptor which has been identified in an array of cell types 46 
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(14)
. Indeed, researchers have compared the efficacy of vitamin D injections, tablets and capsules at 47 
increasing total 25(OH)D concentration 
(15, 16)
. Yet to our knowledge no study to date has directly 48 
compared the total 25(OH)D response between oral spray and capsule vitamin D3 supplementation 49 
in a Western population residing at a northerly latitude. Therefore, the aim of this study was to 50 
compare the efficacy of two forms of vitamin D3 supplement; liquid capsules and oral spray 51 
solution, at increasing total 25(OH)D concentrations during wintertime in healthy adults.  52 
Materials and methods 53 
Study overview 54 
This randomised, open-label, two-period crossover study was conducted at the University of Ulster 55 
Coleraine at a latitude of 55º N during wintertime when vitamin D synthesis is minimal at this 56 
latitude (October 2015 to March 2016). The study was approved by the University of Ulster 57 
Research Ethics Committee (REC/15/0083), registered at www.clinicaltrials.gov  (NCT02608164) 58 
and was conducted in accordance to the declaration of Helsinki. The protocol comprised two 4-59 
week interventions that were separated by a 10-week washout period, Figure 1. Washout length 60 
was based upon the United States Food and Drug Administration (FDA) guidelines, which state 61 
that a washout 5x the plasma half-life of the measured substance is required to achieve over 95% 62 
elimination from the body, and evidence that the plasma half-life of total 25(OH)D is 63 
approximately 2-weeks 
(17-19)
. 64 
Subjects 65 
A total of 22 healthy adults (males n=10 and females n=12) were recruited from the university and 66 
local area through circular e-mails and online advertisements. Participants completed a screening 67 
questionnaire and were provided with an information sheet prior to study enrollment. Inclusion 68 
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criteria consisted of being over 18 years of age and apparently healthy. Exclusion criteria were as 69 
follows; intending to consume a supplement containing vitamin D at any point during the study; 70 
currently taking medication(s) known to influence vitamin D metabolism [calcium-channel 71 
blockers, anticonvulsants, cardiac glycosides, thiazide diuretics, isoniazid, statins, active vitamin D 72 
metabolites / calcitonin, laxatives (regular/continued use)]; those following a vegan diet, sun bed 73 
users and those planning a sun holiday at any point during the study. Informed consent was 74 
obtained at the first appointment. All appointments took place at either the Human Intervention 75 
Studies Unit at the University of Ulster, Coleraine or the Northern Ireland Clinical Research 76 
Facility in Belfast City Hospital. 77 
Supplements and compliance 78 
The order in which vitamin D3 oral sprays or capsules were provided, was determined by the 79 
clinical trials manager using MINIM randomisation software with an allocation ratio of 1:1 
(20)
. 80 
Participants were asked to consume their respective supplement at the same time each day (in the 81 
morning prior to breakfast). Those allocated to sequence allocation one received an oral spray 82 
solution containing 3000IU (75µg) vitamin D3, per spray, and were instructed to self-administer a 83 
single spray targeting the buccal membrane on a daily basis for a period of 4 weeks. Those 84 
allocated to sequence allocation two were instructed to consume three 1000IU (25µg) vitamin D3 85 
capsules per day with water for a period of 4 weeks. Following the washout period, participants 86 
completed a final 4-week supplementation phase on the opposite treatment. Capsules were 87 
provided in pill boxes to aid compliance. The vitamin D3 content of a single oral spray bottle 88 
solution from the supplied batch and 50g of capsule matrix were confirmed by an independent 89 
laboratory using high-performance liquid chromatography. The oral spray solution tested contained 90 
75±7.5µg vitamin D3/spray and the capsules sample contained 25±5µg D3/capsule. The 3000IU 91 
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(75µg) daily dose chosen fell below the 4000IU (100µg) daily tolerable upper limit for vitamin D 92 
specified by the European Food Safety Authority 
(21)
. Participants were asked to return pill boxes 93 
and oral spray bottles at the end of each supplementation phase, to enable estimation of 94 
compliance. Percentage compliance to capsule supplementation was determined by capsule 95 
counting post-intervention and by dividing the actual number of days on intervention by the 96 
expected number of days and multiplying by a factor of 100. The method used to calculate 97 
percentage compliance to oral spray supplementation is described elsewhere 
(22)
. 98 
Blood collection and processing 99 
Participants were instructed to fast from 10pm the night prior to blood sampling and encouraged to 100 
drink water as usual. Blood samples were obtained from the antecubital vein by a trained 101 
phlebotomist. Samples were processed within 1 hour of collection. Following inversion, serum 102 
samples were allowed to clot for up to 60 minutes and plasma samples placed in refrigeration until 103 
centrifugation. Tubes were centrifuged at 2200rpm for 15 minutes at 4˚Celsius. Separated fractions 104 
of serum and plasma were then transferred into 0.5mL aliquots and stored at -80˚Celsius until 105 
further analysis. 106 
Blood analysis 107 
Total serum 25(OH)D concentrations [25(OH)D2 plus 25(OH)D3] were measured by liquid 108 
chromatography-tandem mass spectrometry (LC-MS/MS) using a commercially available kit (API 109 
4000; AB SCIEX; Chromsystems Instruments and Chemicals GmbH; MassChrom 25-OH-Vitamin 110 
D3/D2). Vitamin D analysis was conducted at the biochemistry department of St James’ Hospital 111 
Dublin. This laboratory is fully accredited to ISO 15189 Standard and complies with the Vitamin D 112 
External Quality Assessment Scheme (DEQAS) and use of the National Institute of Standards and 113 
Technology 972 vitamin D standard reference material. The respective inter- and intra-assay 114 
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coefficients of variation were 6.5% and 7.5% respectively. Intact parathyroid hormone (PTH) 115 
concentrations were measured in duplicate using a commercially available enzyme-linked 116 
immunosorbent assay (MD Biosciences Inc., Minnesota, USA). Intra and inter-assay coefficients 117 
of variation were 4.52% and 6.18% respectively. Serum calcium, albumin and creatinine 118 
concentrations were quantified, in duplicate, using an ILab 650 clinical chemistry analyser 119 
(Instrumentation Laboratory, Massachusetts, United States). Intra-assay coefficients of variation 120 
were 1.11%, 0.80% and 1.19% respectively. The following equation was applied to total calcium 121 
and albumin concentrations to account for protein-bound calcium; Adjusted calcium = 0.04 +	total 122 
calcium	×	(40	− albumin) 
(23)
 with adjusted calcium concentrations used in analyses thereafter. To 123 
confirm healthy renal function, the Modification of Diet in Renal Disease (MDRD) equation 
(24)
 124 
was used in order to obtain estimated glomerular filtration rate (eGFR) from creatinine 125 
concentrations. 126 
Dietary vitamin D intake 127 
Participants completed a validated vitamin D food frequency questionnaire to estimate habitual 128 
dietary vitamin D intake on one occasion, owing to the minimal contribution of dietary vitamin D 129 
to overall vitamin D status in the Western diet 
(25)
. Researchers asked participants a series of 130 
questions regarding their consumption of foods containing vitamin D and a food atlas was used to 131 
estimate portion sizes 
(26)
. 132 
Statistical analysis 133 
An a priori power calculation with a two-sided significance level of 5% and power at 80% 134 
concluded that a total of 22 participants were required to observe a significant 9.4nmol/L 135 
difference in the total 25(OH)D response between two different vitamin D3 supplementation 136 
strategies (GPower version 3.1) 
(16, 27)
. This figure was inclusive of an estimated 40% dropout rate. 137 
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All further statistical analysis was performed with the Statistical Package for the Social Sciences 138 
(SPSS) (IBM SPSS Statistics for Windows, version 22.0, IBM Corp, Armonk, NY), with 139 
significance set at P<0.05. Normality of data was assessed using the Shapiro-Wilk test. Age and 140 
PTH concentrations were skewed and therefore transformed using the logarithmic function to 141 
achieve a more normal distribution prior to further analysis. Missing data were subject to intention 142 
to treat (ITT) analysis in-line with the Consolidated Standards for Reporting Trials (CONSORT) 143 
guidelines 
(28)
. As such, statistical analyses included all participants randomised at baseline (n=22). 144 
As data were deemed to be missing completely at random, ITT consisted of 40 imputed datasets 145 
with minimum and maximum value constraints pre-specified using per protocol data. An overview 146 
of imputed data is provided in Figure 1. Comparisons between sequence allocations at baseline 147 
were made using and independent samples t test. Potential carryover effects were ruled out using a 148 
paired t test that compared total 25(OH)D concentration at baseline and at the beginning of the 149 
second supplementation phase. Following this, a time by treatment interaction was ruled-out using 150 
an independent t test that compared overall change in total 25(OH)D concentration according to 151 
sequence allocation. Data from both sequence allocations were then pooled into a single database 152 
and the effect of oral spray versus capsule vitamin D3 supplementation on total 25(OH)D 153 
concentration tested using analysis of covariance controlling for pre-intervention total 25(OH)D 154 
concentration. Magnitude of change in total 25(OH)D concentration was calculated as percentage 155 
change from baseline by dividing the change in total 25(OH)D concentration during intervention 156 
by baseline concentration and multiplying by a factor of 100. 157 
Results 158 
The participant flow is detailed in Figure 1. Overall, 4 participants did not complete the trial as a 159 
result of sun holidays (n=2), illness unrelated to intervention (n=1) or undisclosed reasons (n=1). In 160 
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participants that returned their oral spray bottle (n=16) and pill boxes (n=19), average compliance 161 
to both interventions exceeded 80%. Nevertheless, two participants did not respond to oral spray 162 
vitamin D supplementation, despite >80% compliance, and were considered outliers. Oral spray 163 
supplementation phase data for these participants was therefore included in ITT. At baseline, 164 
vitamin D sufficiency (>50nmol/L), insufficiency (31-49nmol/L) and clinical deficiency 165 
(<30nmol/L) was evident in 59%, 23% and 18% of participants respectively. Overall, baseline 166 
mean ± SD total 25(OH)D concentration averaged 59.76±29.88nmol/L, representing clinical 167 
sufficiency while dietary vitamin D intake averaged 6.25±6.24µg/day. Baseline characteristics of 168 
participants in each sequence allocation are provided in Table 1. There was no evidence of a 169 
carryover effect from the first supplementation phase with respect to mean ± SD total 25(OH)D 170 
concentration [59.76±29.88nmol/L (baseline) versus 59.90±19.86nmol/L (end of washout), 171 
P=0.977]. There was also no difference in the response to vitamin D3 supplementation according to 172 
sequence allocation, [32.70±16.15nmol/L (sequence allocation 1) versus 23.82±18.62nmol/L 173 
(sequence allocation 2), P=0.098]. Participant characteristics before and after supplementation with 174 
vitamin D3 capsules or oral spray solution
 
are presented in Table 2.
 
ANCOVA revealed no 175 
significant difference in the mean ± SD change from baseline in total 25(OH)D concentration 176 
between oral spray and capsule supplementation methods (26.15±17.85 versus 30.38±17.91nmol/L 177 
respectively (F=1.044, adjusted r
2
=0.493, P=0.313). Use of ITT did not change the study outcome 178 
when compared with per protocol analysis (F=-4.709; r
2
=0.476, P=0.329). Percentage change 179 
from baseline in total 25(OH)D concentration for oral spray and capsule interventions was +44% 180 
and +51% respectively. There was no evidence of hypercalcemia (>2.2mmol/L) in response to 181 
intervention; highlighting the safety of the dose and duration provided.  182 
Discussion 183 
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This randomised, open-label crossover study has revealed, for the first time in healthy Western 184 
adults residing at a northerly latitude (55º N), that vitamin D3 supplied in oral spray form is equally 185 
effective at raising total 25(OH)D concentrations when compared to capsule supplementation. Our 186 
findings therefore advocate use of oral spray vitamin D3 as a suitable alternative, if desired, to 187 
capsule supplementation in the general population. There is a lack of comparable studies however 188 
a recent crossover trial that compared oral spray and capsule vitamin D3 supplementation [1000IU 189 
(25µg) daily for 4 weeks] in healthy Indian adults (assigned to oral spray, n=7; capsules, n=7; 190 
control, n=6) and patients with gastrointestinal malabsorption (assigned to oral spray, n=7; 191 
capsules, n=7; control, n=6) found that oral spray supplementation was superior to capsules in both 192 
healthy and patient population groups, contrasting with the results of the current study 
(9)
. Although 193 
Satia and colleagues employed washout phase only 2x the plasma half-life of 25(OH)D and did not 194 
account for sunlight exposure in statistical analyses, these factors are unlikely to account for the 195 
abovementioned difference between studies as total 25(OH)D concentrations returned to baseline 196 
concentrations following washout and remained stable in the control group throughout the study. 197 
The magnitude of change in total 25(OH)D concentration (mean percentage increase from 198 
baseline) was similar between the current study and the findings of Satia and colleagues for oral 199 
spray supplementation (+44% versus +43% respectively) however this was not the case for capsule 200 
supplementation (+51%, versus +22% respectively). The permeability and absorption potential of 201 
the gastrointestinal tract is known to vary according to an individual’s geographical location, with 202 
Asians exhibiting lower absorption and membrane permeability than Europeans 
(29)
. Although the 203 
exact mechanism responsible for this disparity is yet to be elucidated it is possible that this 204 
phenomenon may explain why Satia and colleagues found the oral spray to be more effective than 205 
capsules at increasing total 25(OH)D concentrations and why their finding was not replicated in the 206 
current study. Furthermore, genetic variation between cohorts may have contributed to differences 207 
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in study outcomes as there is growing evidence of ethnic differences in the frequency of VDR 208 
polymorphisms known to impact vitamin D metabolism 
(30)
.  209 
Our findings demonstrate that oral spray vitamin D3 is just as effective as capsule supplementation 210 
at increasing total 25(OH)D concentrations in the healthy adult population. Nevertheless, the 211 
ability of oral spray vitamin D3 to bypass the intestinal absorption route may well prove superior 212 
for those with gastrointestinal malabsorption syndromes and for individuals with difficulty 213 
swallowing such as the elderly, young children and babies 
(8, 31)
. It is important to recognise that, 214 
irrespective of the route of absorption, both oral spray and capsule-based vitamin D3 must first 215 
undergo hepatic hydroxylation prior to forming 25(OH)D which is detected by LC-MS/MS 
(32)
. As 216 
such, in those with malabsorption syndromes, any potential long-term benefit of oral spray 217 
supplementation over capsules on total 25(OH)D concentrations would likely be derived from 218 
enhanced absorption rather than as a result of faster entry of vitamin D3 into systemic circulation. 219 
This concept is supported by the similar extent to which both oral spray and capsule 220 
supplementation methods raised total 25(OH)D concentrations in the current study. Additional 221 
well-designed crossover trials are required in order to elucidate the potential benefits of oral spray 222 
vitamin D in patients with gastrointestinal malabsorption.  223 
The low dietary vitamin D intake reported in this study is comparable to numerous others 224 
conducted across Ireland and is a result of limited dietary sources that are not readily consumed 
(22, 
225 
33, 34)
. The Scientific Advisory Committee on Nutrition (SACN) recently proposed a vitamin D 226 
recommended nutrient intake (RNI) of 10µg/day for the entire UK population 
(35)
. However, 86% 227 
of participants in this study failed to meet this recommendation thus reinforcing the important role 228 
of safe summertime UVB exposure and effective wintertime supplementation strategies in 229 
optimising vitamin D status. 230 
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Strengths of this study include use of an adequate washout phase, independent vitamin D content 231 
verification of supplements, inclusion of male and female participants and rigorous statistical 232 
analysis that accounted for baseline total 25(OH)D concentrations. However, it remains unknown 233 
how oral spray and capsule vitamin D3 supplementation methods compare over longer-term 234 
interventions exceeding 4 weeks in duration. Future studies in this area should focus on comparing 235 
the effectiveness of oral spray vitamin D3 supplementation against alternative methods in those 236 
with gastrointestinal malabsorption. If our findings are replicated or oral spray vitamin D3 is indeed 237 
found to be advantageous over capsules in these individuals; oral spray supplementation may offer 238 
a non-invasive alternative to injections and therefore lower patient administration burden. 239 
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 Tables and Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Body mass index, BMI; 25-hydroxyvitamin D, 25(OH)D; parathyroid hormone, PTH, estimated glomerular filtration 
rate, eGFR
  
a 
All values are provided as mean ± SDs  
b
 Difference between sequence allocation values at baseline compared using an independent t test 
Table 1.  Baseline participant characteristics by sequence allocation 
a
 
 Sequence allocation  
Measure Capsules  oral spray (n=11) Oral spray  capsules (n=11) P
 b
 
Age, y 23.0 2.7 27.4 8.4 0.157 
Height, cm 168.3 10.2 171.6 8.8 0.427 
Weight, kg 67.4 17.8 76.4 10.8 0.166 
BMI, kg/m
2
 23.4 3.8 25.8 3.2 0.177 
Total 25(OH)D, nmol/L 62.4 31.6 57.1 29.3 0.686 
Adjusted calcium, mmol/L 2.3 0.1 2.2 0.1 0.114 
PTH, pg/mL 43.5 15.5 53.2 29.1 0.647 
eGFR, mL/min/1.73m
2
 92.7 10.8 90.6 7.9 0.608 
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Abbreviations: Body mass index, BMI; 25-hydroxyvitamin D, 25(OH)D; parathyroid hormone, PTH, estimated glomerular filtration 
rate, eGFR 
a 
All values are provided as mean ± SDs
  
b
 Difference between pre versus post-intervention values tested using a paired t test 
c
 Significantly different from pre-intervention mean, P<0.001
Table 2.  Participant characteristics before and after supplementation with vitamin D3 capsules or oral spray solution
 a
 
 Treatment and time point  
 Capsules (n=22)  Oral spray solution (n=22) 
Measure Pre-intervention Post-intervention P
 b
  Pre-intervention Post-intervention P
 b
 
Age, years 25.2 6.5 25.2 6.5 0.329  25.2 6.5 25.2 6.5 1.000 
Weight, kg 71.5 15.1 71.0 15.1 0.578  70.9 14.9 70.8 15.0 0.747 
BMI, kg/m
2 
24.4 3.6 24.2 3.6 0.574  24.2 3.5 24.2 3.5 0.649 
Total 25(OH)D, nmol/L 60.0 26.3 90.4 21.0 0.001
 c
  59.6 24.4 85.8 19.4 0.001
 c
 
Adjusted calcium, mmol/L 2.2 0.1 2.2 0.1 0.783  2.2 0.1 2.2 0.1 0.666 
PTH, pg/mL 50.3 25.5 52.2 19.3 0.373  52.1 26.0 48.2 27.3 0.475 
eGFR, mL/min/1.73m
2
 91.0 9.3 92.1 11.8 0.347  90.8 11.2 88.4 10.8 0.173 
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Excluded (n=12) 
Not meeting inclusion criteria (n=5) 
Unable to contact (n=7) 
Assessed for eligibility (n=34) Enrolment 
4-week supplementation phase 
10-week washout and crossover 
Lost to follow up (n=0) 
 
Lost to follow up (n=2) 
Sun holiday, no longer wished to participate 
3000IU vitamin D3 capsules (n=9) 
Received allocation (n=9) 
Follow-up 
4-week supplementation phase 
Lost to follow up (n=1) 
Illness unrelated to the intervention 
Lost to follow up (n=1) 
Sun holiday 
Completed trial (n=8) Completed trial (n=10)  
Included in intention to treat analysis (n=22) 
Allocated to 3000IU vitamin D3 capsules (n=11) 
Received allocation (n=11) 
Allocated to 3000IU vitamin D3 oral spray (n=11) 
Received allocation (n=11) 
Allocation 
Analysis 
Randomisation (n=22) 
Follow-up 
3000IU vitamin D3 oral spray (n=11) 
Received allocation (n=11) 
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Figure 1. CONSORT flow diagram. A total of 34 healthy adults expressed interest in the study 
and completed screening questionnaires. Overall, 12 individuals were excluded for either not 
meeting inclusion criteria (n=5) or were unable to contact (n=7). Twenty-two healthy adults 
satisfied inclusion criteria and were randomised to receive 3000IU (75µg) vitamin D3 daily in 
either an oral spray (n=11) or capsules (n=11) for 4 weeks. Two participants were lost to follow-
up during the first supplementation phase owing to sun holiday (n=1) or nor longer wishing to 
participate (n=1). Following a 10-week washout, participants crossed-over to the opposite 
treatment for a final 4 weeks. Two further participants were lost to follow-up in the second 
supplementation phase owing to sun holiday (n=1) or illness unrelated to the intervention (n=1). 
Overall, 18 participants completed the study per protocol. All participants randomised at 
baseline were included in the final analysis. 
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported on 
page No 
Title and abstract 
 1a Identification as a randomised trial in the title Title page 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) Page 2 
Lines 1-18 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 
 
Pages 3-4 
Lines 23-51 
2b Specific objectives or hypotheses Page 4 
Lines 50-52 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio Page 4-5 lines 
67- 73 and Page 
5 lines 78-79 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons N/A 
Participants 4a Eligibility criteria for participants Pages 4-5 
Lines 66-72 
4b Settings and locations where the data were collected Page 5 
Lines 55-57 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
Pages 5 
Lines 78-90 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
Page 4 lines 50-
52 
Pages 6-7 lines 
98-114 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined Page 7 
Lines 131-135 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
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Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence Page 5  
Lines 78-79 
8b Type of randomisation; details of any restriction (such as blocking and block size) Page 5  
Lines 78-79 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
Page 5  
Lines 78-79 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
Page 5  
Lines 78-79 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
N/A 
11b If relevant, description of the similarity of interventions Page 5 
Lines 87-90 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes Page 8 
Lines 149-154 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses N/A 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
Pages 18-19 
(Figure 1) 
13b For each group, losses and exclusions after randomisation, together with reasons Pages 18-19 
(Figure 1) and 
Page 8 lines 
156-157 
Recruitment 14a Dates defining the periods of recruitment and follow-up Page 4 Line 56-
57 
14b Why the trial ended or was stopped N/A 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Page 16  
(Table 1) 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
Pages 18-19 
(Figure 1) 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
Page 9 
Lines 172-177 
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17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
N/A 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) Page 9 
Lines 177-179 
(No harms 
observed) 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses Pages 11 
Lines 229-231 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings Pages 11 
Lines 229-231 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence Pages 9-11 
Lines 181-235 
Other information  
Registration 23 Registration number and name of trial registry Title Page 
Protocol 24 Where the full trial protocol can be accessed, if available Title Page 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders Page 12 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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